Hydration rehydrates share price with non-US asset sale
Sponsored
Bulls N'Bears

Hydration rehydrates share price with non-US asset sale

This week’s Bulls N’ Bears Runner of the Week is … Hydration Pharmaceuticals. The company sold its non-US assets for a sum five times its market capitalisation.

  • byCraig Nolan

Latest

It introduced Ozempic to the world. Now it must remake itself

It introduced Ozempic to the world. Now it must remake itself

Danish drugmaker Novo Nordisk has eclipsed French luxury group LVMH to become Europe’s most valuable company – thanks to demand for diabetes and weight-loss drugs.

  • byEshe Nelson
The artificial heart set to transform medicine – and the Aussie who invented it

The artificial heart set to transform medicine – and the Aussie who invented it

Biomedical engineer Daniel Timms lost his father to heart disease,but their kitchen-top tests helped him hone a radical idea.

  • byAmanda Hooton
The April 20 Edition
Magazine
Good Weekend

The April 20 Edition

The Aus-designed artificial heart set to revolutionise medicine| Preppers go mainstream| A sperm donor’s message to his progeny

13stories
Our track record in medical innovation can only be maintained with funding support
Opinion
Health

Our track record in medical innovation can only be maintained with funding support

Australian researchers are responsible for a series of globally significant medical inventions and innovations.

  • byThe Herald's View
Future of medical research in doubt as question mark lingers over $45 million funding

Future of medical research in doubt as question mark lingers over $45 million funding

The future of a government funding program which has assisted teams developing artificial hearts and turning spider venom into drug therapies is in doubt.

  • byMary Ward
Advertisement
His dad was dying. So Daniel built a world-first artificial heart – with pipes and magnets
Exclusive
Healthcare

His dad was dying. So Daniel built a world-first artificial heart – with pipes and magnets

Australia will spend $50 million building the world’s first long-term artificial heart,after the original prototype was built with pieces bought from Bunnings.

  • bySherryn Groch
Failed drug trial overshadows CSL’s bumper profits

Failed drug trial overshadows CSL’s bumper profits

Investors have punished the company’s share price for the second day in a row – despite it booking revenue of $12.3 billion for the half-year to December 31.

  • byDavid Swan
Health behemoth CSL sheds $7b in value after heart drug fails trial

Health behemoth CSL sheds $7b in value after heart drug fails trial

Shares in the blood plasma treatments maker were trading nearly 5 per cent lower following the results.

  • byMillie Muroi
Australia underspends on this key area. It may put national security at risk
Exclusive
Education

Australia underspends on this key area. It may put national security at risk

Australia’s underinvestment in research is becoming a national security issue,some university heads argue,ahead of a landmark review and the AUKUS deal.

  • bySherryn Groch andDaniella White
Growing frustration for seaweed farmer at Labor’s ‘incredibly slow’ action to cut cow methane

Growing frustration for seaweed farmer at Labor’s ‘incredibly slow’ action to cut cow methane

After rubbing shoulders in Singapore with Prince William,Sea Forest founder Sam Elsom is eager for the Albanese government to back his plan to help save the planet.

  • byChris Barrett